Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Improving Stroke Outcomes: Attenuating Progression And Recurrence
Funder
National Health and Medical Research Council
Funding Amount
$9,331,996.00
Summary
Stroke is the second most common cause of death and major cause disability. There are few proven interventions, so we need to introduce new ones. We developed a bench to bedside program to introduce new stroke therapies and its early secondary prevention. Our general goal is to provide evidence for their effectiveness and safety. We will use animal stroke models, markers in the blood to help diagnose and predict stroke outcome and imaging to help select patients for several clinical trials.